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1. Introduction 
Fragment-based lead discovery offers more efficient sampling 
of medicinal chemistry space and exploiting optimal interactions 
with the protein target that makes this approach increasingly 
popular.
1,2
 Since emphasis is placed more on interaction 
efficiency rather than binding affinity per se, sensitive 
biophysical detection techniques including X-ray 
crystallography, NMR spectroscopy
3,4
 and surface plasmon 
resonance,
5
 but also thermal shift assays
6
 and biochemical 
screening
7
 are used in the primary screening phase of fragment-
based drug discovery (FBDD) programs. 
G protein-coupled receptors (GPCRs) form a significant 
portion of potential targets of novel drugs,
8
 thus application of 
fragment screening to GPCRs is a well-founded objective. While 
for soluble targets numerous successful FBDD programs are 
documented,
1,9
 reports on fragment screening for membrane 
proteins are much sparser. SPR was applied successfully using 
immobilized and tagged membrane proteins
10-12
 while researchers 
from Heptares and ZoBio reported the use of target immobilized 
NMR screening (TINS) on thermostabilized GPCRs.
10,13
 A novel 
adenosine A3 receptor specific fluorescent label enabled 
development of a fluorescence intensity-based whole cell binding 
assay
14
 capable of identifying low affinity ligands of A3. Apart 
from these successful examples, where challenging target-
specific preparations were crucial for the actual screening 
process, some experiences with more generic assay formats for 
probing membrane proteins have been reported as well.
15-17 
Often, drug discovery programs require ligands that stimulate 
or potentiate membrane receptors. Although the understanding on 
the molecular basis of GPCR function increased tremendously in 
the last years,
18
 the structural basis of distinct biological 
responses is still poorly understood. GPCR activation pathways 
have only recently been tackled by crystallographic
19
 and 
molecular modeling
20,21
 efforts. Cellular in vitro assays, where 
the molecular target is presented in a biologically relevant 
functional form, available at most screening laboratories, could 
be theoretically applied widely to identify ligands for membrane 
targets of different functional activity. Despite good availability, 
some concerns about these assays arise: assay interference caused 
by high test concentrations, sensitivity of functional assays and 
the lack of structural information. In this study our aim was to 
assess the utility of in vitro biological assays to fragment-based 
lead discovery for GPCR agonists and to explore hit validation 
strategies following fragment hit discovery and our findings on 
adrenergic α2C receptor are reported. 
The adrenergic α2C receptor belongs to class A GPCRs and 
agonists selectively activating this receptor might offer 
therapeutic benefits in analgesia, anesthesia or various CNS 
indications.
22,23
 The major limitation for development of α2C 
receptor agonists has proven to be the high degree of similarity to 
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undesired homologues, especially α2A, and discovery of 
sufficiently selective ligands has been found troublesome. We 
speculated that identifying novel molecular fragments efficiently 
binding to α2C could provide sufficient room to improve subtype 
selectivity. 
Moreover, as the structure of the adrenergic α2C receptor 
binding site is not available yet, homology modeling was 
performed in order to do a head-to-head comparison of 
experimental and virtual agonist fragment screening and to 
provide binding hypotheses for the identified hit compounds. 
Although the activation process brings about little structural 
change in the binding site, it was shown that molecular docking 
of agonist ligands to activated structural models is preferred
24
 and 
an agonist-bound homology model of the CB2 receptor was 
successfully used in identifying novel agonists from virtual 
screening.
25
 Activated structural models generated using 
molecular dynamics simulation were also shown to be capable of 
retrieving agonist ligands in retrospective virtual screening 
studies.
21,26 
2. Results and discussion 
2.1. Experimental fragment screening 
In preparation for a fragment screening for the identification 
of α2C agonists, all options for screening assays were considered. 
In lack of a thermostabilized receptor variant and a validated 
immobilization technique for the target, radioligand displacement 
assay and functional assay utilizing a chimeric G protein
27
 have 
been selected for further evaluation. 160 diverse compounds 
selected from the Maybridge Rule of Three core library have 
been tested in both assay formats at 250 µM concentration. While 
in the functional test only 3 compounds displayed agonistic 
activity above 50%, 48 compounds possessed activity above 50% 
in the displacement assay. This phenomenon was specific to α2C, 
as radioligand displacement at an unrelated peptidergic receptor 
resulted in no actives from the same representative set of 
fragments. As we opted to assess the performance of a biological 
screening method in a generic setting, the unusually high hit rate 
in a binding test was taken with precaution and the functional 
calcium mobilization assay was chosen for hit identification. 
3071 compounds fulfilling the fragment criteria were screened 
at 250 µM in duplicates in the cell-based functional assay. The 
screen was performed with an average Z’ of 0.80 and average Z 
of 0.63, indicating low variability in assay.
28
 An activity 
threshold of 50% resulted in 318 actives corresponding to 10.3% 
of screened compounds. Upon retesting these samples, 86 
compounds gave higher than 50% response at 250 µM. This 
surprisingly low confirmation rate (27%) was presumably the 
result of the inter-day variability in the sensitivity of the cellular 
assay, as during confirmation most compounds (217 out of 318) 
surpassed the 50% activity threshold at 500 µM and the EC50 of 
reference agonist UK14,304 was also slightly right-shifted at 
retesting (data not shown). 
To rule out nonspecific activity caused by the high screening 
concentration, all actives were tested for their agonistic like 
effect on sst4 receptor expressing cells utilizing the same protocol 
as the α2C assay. 21 of the 86 confirmed actives displayed less 
than 30% fluorescence response at the sst4 receptor and 20 of 
them were pure samples as determined with HPLC/MS. To 
confirm target specific interaction, the resulting 20 samples 
underwent radioligand displacement assay on α2C, where 16 
compounds displayed concentration dependence for binding and 
at least 50% displacement at 500 µM. Interestingly, functional 
responses elicited by 3 of the remaining 4 compounds could be at 
least partially inhibited by the orthosteric α2 antagonist MK-912. 
Our fragment screening campaign thus led to the identification of 
16 validated agonist fragment hits at the α2C receptor. 
Next, all hits were characterized for binding affinity, agonist 
potency and efficacy at the α2C receptor utilizing the above 
assays. To assist evaluation of binding efficiency, ligand 
efficiency (LE) and ligand-efficiency-dependent lipophilicity 
(LELP) were derived from Ki values as described in the 
literature.
29,30
 Table 1 demonstrates representative data for the 
validated hits. Numerous chemically diverse highly potent and 
efficient fragment hits were identified from this commercially 
available screening set. Interestingly, functional hit profiles 
showed a high degree of heterogeneity: low efficacy and high 
potency hits displaying partial agonism relative to UK14,304 in 
the calcium assay with equal affinity as full agonist of low 
potency were observed (e.g. compare effects of compounds 2 and 
4 in Figure 1 and Table 1). Finally to assess novelty, chemical 
similarity to known α2C receptor ligands from the ChEMBL 
bioactivity database was calculated and the most similar 
structures are shown in Table 1. Fragment 1 is a known alpha 
adrenergic agonist from the imidazoline family. Compound 4 is a 
known dopaminergic ligand, however, its adrenergic effect has 
not yet been reported. The rest of the fragments had moderately 
similar or no analogues among known α2C ligands. 
Screening fragments at high concentration in biological assays 
has its limitations, most notably higher risk of nonspecific effects 
observed, lower sensitivity and lack of structural information on 
binding. The fact that the hit rate for α2C agonists in a functional 
assay was comparable to that of other screening approaches 
indicates that assay interference did not hinder screening in 
general in the biological setting. Although a significant portion of 
hits were discarded after counter-screening, it has to be noted that 
owing to potentially low specificity of fragment hits
17
 
straightforward counter-screening at an unrelated target could 
significantly overestimate non-specificity. Thus, orthogonal on-
target assays confirming molecular mechanism of action should 
be preferred instead. Moreover, several in vitro assays are 
available less prone to nonspecific interference.
31,32
 Sensitivity in 
the biological assay in contrast is expected to be inferior to those 
in biophysical formats, although the latter methods often also 
require demonstration of relevance of binding in a functional 
context. The limitation of reduced sensitivity can 
 
Figure 1. Diversity of binding and functional responses with fragment 
hits. Concentration response curves for compounds 2 and 4 in radioligand 
displacement (graphs A and C) and agonistic effect in calcium mobilization 
assay (graphs B and D) expressed as percentage of maximal effect.
Table 1. Pharmacological parameters of fragment hits. 
Cpd. Structure 
Radioligand displacement Calcium mobilization 
LE LELP 
Most similar compound in 
ChEMBL 
pKi 
Emax / % 
pEC50 
Emax / % 
mean SD mean SD 
1 
 
8.64 0.10 102 7.26 0.21 55 0.74 3.0 
Naphazoline 
(exact) 
2 
 
7.93 0.02 100 <3.30 N.D. >75 0.64 4.5 
 
3 
 
7.14 0.17 100 6.76 0.24 60 0.70 2.1 
 
4 
 
7.08 0.06 92 5.86 0.10 70 0.51 3.7 
 
5 
 
6.27 0.05 92 <3.30 N.D. >66 0.57 4.3 
 
6 
 
6.19 0.12 92 5.50 0.39 49 0.65 2.4 
 
7 
 
5.97 0.15 98 5.46 0.15 56 0.41 5.9 
 
8 
 
5.93 0.01 97 <3.30 N.D. >105 0.62 4.1 
 
9 
 
5.28 0.10 102 3.32 0.11 87 0.36 5.6 
 
10 
 
5.14 0.04 99 <3.30 N.D. >88 0.32 7.7 
 
11 
 
5.08 0.06 104 <3.30 N.D. >51 0.36 6.0 
 
12 
 
4.98 0.06 81 <3.30 N.D. >77 0.42 2.7 
 
13 
 
4.82 0.10 78 3.47 0.17 123 0.41 5.8 
 
14 
 
4.81 0.09 81 3.20 0.12 93 0.36 4.9 
 
15 
 
4.81 0.18 81 <3.3 N.D. >82 0.35 7.5 
 
16 
 
4.65 0.07 102 3.83 0.06 55 0.35 7.7 
 
17a 
 
5.82 N.D. 100 <3.3 N.D. >36 0.57 1.9 
 
aThe only hit from the MayBridge validation library with sst4 response <10% at 250 µM. 
N.D. Not determined 
be compensated by screening compounds of slightly higher 
complexity than those in X-ray or NMR studies,
33
 as the higher 
throughput of established plate-based biological assays enables 
screening of larger compound libraries. These libraries still 
sample chemical space more efficiently than conventional HTS 
collections while they are expected to produce higher affinity 
ligands than less complex libraries.
34
 Lastly, lack of structural 
information is definitely a shortcoming of biological fragment 
screening and it is yet to be demonstrated that efficient fragment 
optimization and evolution is possible on GPCR targets with 
either biophysical or biological methods. 
2.2. Virtual fragment screening 
The homology model of the activated α2C receptor was 
constructed using the human adrenergic β2 X-ray structure 
crystallized with a nanobody stabilizing the active state as 
template. The binding site was optimized using known agonists 
of the α2C receptor in the Schrödinger Induced Fit Docking 
protocol. The best structure for virtual screening was selected 
based on retrospective enrichment studies over a ligand set of 
known agonists and property matched decoys molecules. Finally, 
the same 3071 fragments that were screened experimentally were 
screened also by docking to the binding site of the α2C homology 
model using Glide. The modeled binding site is consequent with 
the mutagenesis and modeling data collected by Mátyus et al.
35
 
but with a more significant contribution to the site by the second 
extracellular loop. The top 1% (30 compounds) of the ranked 
ligand set went through the same hit validation protocol as 
described previously. 5 of the 30 compounds exhibited higher 
than 50% response in the cell-based α2C functional assay, but 
three of these also displayed higher than 30% fluorescence 
response at the sst4 receptor. Finally, compounds 10 and 14 were 
identified from the virtual screening as validated hits preferring 
α2C binding. No false negatives of the primary experimental assay 
were identified. This ratio represents an enrichment factor of 12.8 
(given that all actives were picked up by the primary assay in 
experimental screening) or less (if there were false negatives left 
unidentified). Docking and confirmation screening results are 
shown in Figure 2. 
Binding modes of the hits feature the characteristic ionic H-
bond with Asp131
3.32
 and the protonated amine tails also form 
cation-π interactions with Phe423
7.39
. The aromatic or biaryl 
cores of the ligands are encased in a hydrophobic cage formed by 
 
Figure 2. Docking scores vs. confirmation screening responses of the 318 
fragments found active in primary screening and the 30 top ranking docked 
fragments. Green markers indicate <30% sst4 response, red markers >30% 
sst4 response, while framed markers indicate the four compounds inactive in 
the radioligand displacement assay. 
 
Val132
3.33
, Leu204
45.52
, Ile211
5.39
, Phe398
6.51
 Phe399
6.52
 and 
Tyr402
6.55
. Only compound 4 is capable of forming H-bonds with 
Ser214
5.42
 and Ser218
5.46
. While these interactions were shown to 
be important in dopaminergic activation (compound 4 is also a 
known dopaminergic ligand), biphenyline- and clonidine-like 
agonists of alpha adrenergic receptors do not usually feature H-
bonding moieties in this position. In our model an ion pair 
Arg192
45.40
-Asp206
45.54
 from the second extracellular loop also 
protrudes in to form the binding site. While the arginine seems to 
be able to form cation-π interactions with aromatic moieties of 
biphenyline-like agonists and the hits identified in this study, no 
polar group in the ligands is seen to interact with this receptor 
feature. The predicted binding modes of the two agonists 
identified in virtual screening 10 and 14 are shown in Figure 3. 
Above the aforementioned interactions these ligands also feature 
a carbonyl group in a position suitable for forming an H-bond 
with the phenolic OH of Tyr402
6.55
 and the tilt between the diaryl 
core allows a perfectly perpendicular arrangement of the tyrosine 
and the ligand aromatic planes. Structural information from 
modeling may also be used to rationally explore fragment 
modifications, however, this was out of the scope of this study. 
2.3. Hit expansion 
Following hit identification we progressed further to expand 
chemical space around hits. Different strategies are known for the 
development of active fragments
36
 and in knowledge of ligand 
efficient modulators of α2C we attempted to optimize hits by 
scanning chemistry space while staying in the same size range. 
Therefore, our internal compound collection was searched for 
compounds with high structural similarity and comparable size to 
the selected hits, the latter expressed in heavy atom count. Up to 
five closest analogues for each hit with a Ki under 10 µM were 
picked from our compound library and tested for both functional 
and binding activity at 20 µM and if active, tested for affinity. 
This lower test concentration was a consequence of some of these 
fragment-sized compounds originating from the standard HTS 
screening library. From the tested compounds several possessed 
clearly improved binding affinity or ligand efficiency (see Table 
2 for selected analogues of 17 and 10) compared to the original 
parent structures, however all second round compounds tested in 
the functional assay turned out to act as antagonists of 
 
 
Figure 3. Predicted binding modes of the two agonists identified in virtual 
screening 10 (top) and 14 (bottom). Protein side chains are depicted in grey 
skeleton, ligands in green skeleton. The top of helix 6 is excluded for clarity. 
 
the receptor, highlighting the high structural similarity of ligands 
with functionally opposing effects at α2C. Hit expansion in this 
case was limited by availability of analogues in our compound 
collection, but in a more general setup it can be augmented from 
commercial sources and by targeted synthesis. 
Table 2. Representative results of structural analogues of 
fragment hits in radioligand displacement and functional 
assays. 
Cpd. Structure pKi Inhibition %a LE/LELP 
18 
 
6.25 -82 0.61 / 1.8 
19 
 
6.62 -87 0.65 / 1.7 
20 
 
4.86 N.D. 0.37 / 6.2 
aFunctional activity: Antagonism of responses elicited by 30 nM UK14,304 at 
20 µM. 
N.D. Not determined 
3. Conclusions 
Fragment screening has proven a viable approach for lead 
identification in drug discovery. Widely applied biophysical 
screening techniques provide efficient, though instrumentation 
intensive methods for various soluble protein targets, however 
their utility for some other major drug target classes like cell 
surface receptors and ion channels remains yet limited. 
Especially in the case of receptor agonists or potentiators, where 
stabilization of putative labile active conformations might be 
required, screening on a functional form of the targets could 
provide a viable alternative. In our study we have tested the 
utility of a conventional cell-based assay for high concentration 
screening of GPCR agonists and performed a head-to-head 
comparison with virtual screening by docking the same library to 
an active-like homology model of the α2C adrenergic receptor. In 
addition to assessing the utility of the cell-based assay in primary 
screening we aimed at evaluation of a proposed screening 
workflow for the validation of fragment hits. Approximately 10% 
of the screened compounds were found active in our fragment 
screen for α2C receptor agonists. This active rate, although much 
higher than under conventional HTS settings, is comparable to 
those reported for GPCRs using diverse assays as TINS, SPR,
10
 
intact cell binding
14
 and conventional biochemical screening.
16,17
 
24% of confirmed hits were found to prefer α2C over an unrelated 
target, and 76% of these displayed significant activity in a 
biochemical assay as well. In virtual screening 2 out of the 16 
hits were identified in the top 1% of the fragment library 
providing moderate enrichment but useful structural information 
on the hits. Our screening campaign successfully identified 
several potent and highly efficient chemotypes for α2C agonists 
proving that conventional screening strategies could be 
successfully utilized in fragment-based lead discovery for 
membrane targets. 
4. Experimental 
4.1. Materials 
UK14,304 and MK-912 and phentolamine were purchased 
from Sigma-Aldrich (St. Louis, MI). L-803,087 was obtained 
from Tocris Bioscience (Bristol, UK). Fragment collections were 
purchased from Maybridge (Cambridge, UK) and Albany 
Molecular Research Inc. (Albany, NY). Fragments were 
dissolved at 50 mM concentration in dimethyl sulfoxide (DMSO) 
and stored at -20 °C until use. 
4.2. Structure-based virtual screening 
The activated human adrenergic β2 X-ray structures 
crystallized with the G protein complex (PDB ID: 3SN6) and 
with a stabilizing nanobody (PDB ID: 3P0G) were considered as 
templates for homology modeling of the adrenergic α2C receptor. 
Side chain orientations in these two structural models are very 
similar but because of the fully resolved ECL2 loop, the latter 
structure was used as a template. The α2C amino acid sequence 
(downloaded from UniProt, www.uniprot.org) was aligned with 
that of the structural template using Prime 3.2
37
 after deletion of 
the nanobody. The sequence alignment is shown in the 
Supplementary information. Known agonists of the α2C receptor 
in clinical and preclinical testing were downloaded from 
Thomson Reuters Integrity (integrity.thomson-pharma.com, 
accessed in July 2013) and prepared using LigPrep 2.6
38
. A single 
proto- and tautomer was generated at pH 7.4 by Epik 2.4
39
. These 
ligands were docked into the binding site of the homology model 
using the Induced Fit Docking (IFD) protocol in the Schrödinger 
Suite 2013.
40
 Tyr127
3.28
, Tyr402
6.55
 and Phe423
7.39
 side chains 
were truncated in the first round of the IFD protocol in order to 
make space for the ligands and H-bonding with Asp131
3.32
 was 
required in both the first docking and the redocking stages of the 
protocol. 
Top ranking complexes from IFD were subjected to 
retrospective enrichment studies using 50 diverse actives from 
the Integrity ligand set and 2450 property matched (molar mass, 
formal charge, clogP and TPSA) decoys from vendor catalogs. 
Docking grids were centered on the reference ligand centroids 
and grid dimension was 10 Å for the inner and 24 Å for the outer 
box. Docking was performed using Glide 5.9
41
 with and without 
H-bond constraints to Asp131
3.32
. 15 poses were included in post-
docking minimization, otherwise settings were the default. The 
structure with the greatest area under the receiver-operating 
characteristic curve (AUCROC = 0.720) was used for docking the 
3071 AMRI fragments in a prospective virtual screening setup. 
These were prepared similarly to the Integrity ligand set using 
LigPrep 2.6 and were docked similarly to the retrospective ligand 
set using Glide 5.9 without using the H-bond constraint to 
Asp131
3.32
. The top 1% (30 fragments) were included in hit 
validation protocols regardless of their primary experimental 
screening results in order to gain a full comparison of virtual and 
experimental screening. Docking scores were plotted against 
confirmatory experimental screening results and the maximal 
enrichment factor was calculated as (ndocking active/ndocking 
all)/(nscreening active/nscreening all) = (2/30)/(16/3071) = 12.8. Similarity 
search was performed against our internal compound database as 
well as compounds having exact experimental data (i.e. inactives 
excluded) on the α2C receptor in the ChEMBL database 
(www.ebi.ac.uk/chembl, accessed in August 2014) using the 
ChemAxon hashed linear fingerprint (fingerprint length = 1024, 
linear path length = 5, bits/path = 2) and Tanimoto similarity 
metric. Molecular properties (heavy atom count and clogP) were 
calculated using ChemAxon cxcalc 6.3.0.
42 
4.3. Cell culture and transfection 
CHO-K1 cells stably expressing recombinant human α2C 
adrenergic receptors and the chimeric Gαqi5 protein were 
generated as described previously.
27
 Cells were cultured in 
Ham’s F12 nutrient mixture supplemented with  L-glutamine 
(Gibco, Life Technologies, Carlsbad, CA) containing 10% foetal 
bovine serum (FBS, Gibco), 2.5 μg/ml amphotericin B, 100 U/ml 
penicillin G, 100 μg/ml streptomycin (Sigma), 1× non-essential 
amino acid mixture (Sigma), 1× RPMI-1640 vitamin solution 
(Sigma), 400 μg/ml G418 (Gibco), 200 μg/ml hygromycin 
(Invitrogen, Life Technologies, Carlsbad, CA). 
CHO-K1 cells stably expressing recombinant human sst4 
receptors and Gα16 were obtained from PerkinElmer (Waltham, 
MA) and were cultured in Ham’s F12 containing 1× PSA 
(Sigma), 10% FBS, 400 μg/ml G418, 250 μg/ml zeocin 
(Invitrogen) according to the description provided by the 
supplier. 
4.4. Membrane preparation from human α2C expressing cells 
Cells were cultured according to the instructions provided by 
the vendor. Harvested cell pellet was transferred into 10 vol. 
(w/v) of buffer A: 5 mM Tris, 5 mM EDTA, 0.2 mM EGTA, 1 
mM phenylmethanesulfonylfluoride (PMSF), pH=7.5, at 22 °C 
and homogenized with Ultra-Turrax homogenizer (IKA, Staufen, 
Germany), at maximal speed for 15 sec. Cell homogenate was 
centrifuged at 30,000 g for 15 min at 4 °C. The resulting pellet 
was washed twice in homogenizing buffer and centrifuged at 
30,000 g for 15 min at 4 °C. The final membrane pellet was 
resuspended in 3 vol (w/v) buffer B: 50 mM Tris, 1 mM EDTA, 
5 mM MgCl2, 1 mM PMSF, pH= 7.4, 22 °C. Protein content was 
determined and membrane homogenate was diluted in buffer B to 
give a total protein concentration of 1 mg/ml. This final 
membrane homogenate was aliquoted and stored at -70 °C until 
use. 
4.5. In vitro [
3
H]UK14,304 binding assay 
After thawing the aliquoted membrane homogenate in 
required quantity (40 μg total protein for each reaction) was 
diluted to a volume of 160 μl in buffer C: Tris 50 mM, pH=7.4, at 
22 °C. Radioligand was diluted in buffer C to a volume of 20 μl 
[
3
H]UK,14,304 (2 nM, specific activity 54 Ci/mmol, 
PerkinElmer), in the presence or absence of drugs (in 20 μl buffer 
C) incubated in a total volume of 0.2 ml for 30 min at 22 °C. For 
non-specific binding 10 µM phentolamine was used. After 
incubation samples were filtered over UniFilter
®
 GF/C
TM
 using 
Filtermate Harvester (PerkinElmer) and washed with 5×1 ml 
buffer C. The plate was dried at 50 °C for an hour and 20 µl 
Microscint
TM
20 (PerkinElmer) scintillation cocktail was added to 
each well. The plate was read in a Microbeta counter 
(PerkinElmer). The ligand displacement by the compounds was 
determined using a minimum of six concentrations in duplicate 
or triplicate, and experiments were repeated at least two times. 
The specific radioligand binding is defined as the difference 
between total binding and the non-specific binding determined in 
the presence of an excess of unlabelled ligand. IC50 values (i.e. 
concentration of compound giving 50% inhibition of specific 
binding) was calculated from concentration-displacement curves 
by sigmoidal fitting using Origin 6.0 software (OriginLab, 
Northampton, MA). Ki values (i.e. inhibition constants) were 
calculated using the Cheng-Prusoff equation: Ki = 
IC50/[1+([L]/KD)], where [L] is the radioligand concentration and 
KD the affinity of the labelled ligand for receptor. KD was 
determined from the Scatchard plot. 
4.6. Fluorometric measurements 
Fluorometric measurements of cytoplasmic calcium 
concentration ( [Ca
2+
]i ) were carried out in α2C/Gαqi5 expressing 
cells and also in sst4/Gα16 expressing cells. Cells were plated in 
standard tissue culture-treated 96-well microplates (40,000 
cells/well) and maintained overnight in a tissue culture incubator 
at 37 °C under an atmosphere of 5% CO2. Next day cells were 
loaded with 100 μl/well Ca
2+
-sensitive dye FLIPR Calcium 4 
(Molecular Devices, Sunnyvale, CA) for 45-60 min at 37 °C. 
Baseline and compound-evoked [Ca
2+
]i-changes were monitored 
with a plate reader fluorometer (FlexStation II
96
, Molecular 
Devices) at 37 °C. The dye was excited at 485 nm and emission 
was sampled at 525 nm at 1.4-s intervals. After monitoring 
baseline fluorescence for 20 s, 50 μl/well agonist/compound 
solution, was added online using the pipettor of FlexStation, and 
fluorescence was recorded for an additional 40 s). Raw 
fluorescence data were transformed to ΔF/F values (F was the 
resting fluorescence preceding compound application and ΔF was 
the increase in fluorescence at a given time). In the case of the 
agonist measurements results were normalized to the response 
evoked by a maximally effective concentration of the reference 
agonists, UK14,304 (α2C, 1 µM) or L-803,087 (sst4, 3 µM). In the 
case of the α2C antagonist measurements, cells were pre-treated 
with compounds/vehicle for 15 min and inhibitory potency of 
compounds was expressed as percent inhibition of the control 
agonist response (30 nM UK14,304, corresponding to an appr. 
EC80 concentration). All experiments were performed at least two 
times, on different days. 
4.7. Fragment screening 
Prior to screening, compounds were transferred to 384-well 
plates and diluted to 750 µM with buffer D (140 mM NaCl, 5 
mM KCl, 2 mM CaCl2, 2 mM MgCl2, 20 mM D-glucose, 10 mM 
HEPES, pH=7.4) using a Biomek NX automated pipettor 
(Beckman Coulter, Brea, CA). Fluorometric calcium 
measurement was performed according to the above protocol 
with slight modifications, on an automated system using 384-
well plates. Cells (12 500 cells/well in 20 μl) were plated into 
384-well tissue culture-treated black wall, clear bottom plates 
(BD Biosciences, Franklin Lakes, NJ) using a Multidrop 384 
dispenser (Thermo Fisher Scientific, Waltham, MA). Next day, 
medium was replaced with buffer D using a BioTek ELx405CW 
automated plate washer and 20 μl/well Ca
2+
-sensitive dye FLIPR 
Calcium 5 (Molecular Devices) was added subsequently using a 
Multidrop dipenser. Cells were incubated for 25 min at 37 °C, 
followed by compound addition and fluorescence measurement 
in a FLIPR Tetra imaging plate reader (Molecular Devices). 
Responses were calculated from ΔF/F values normalized to 
control wells for vehicle (DMSO) and reference agonist (3 µM 
UK-14,304 or 5 µM L-803,087 for α2C and sst4, respectively) and 
expressed as percentage of positive control effect. Z’ and Z 
parameters were calculated as described by Zhang et al.,
28
 the 
latter from partial controls (displaying 63% activity in average). 
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